# Arcus Biosciences Inc. (RCUS) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Healthcare / Biotechnology. Price $29.66, market value $3.7 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Arcus Biosciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 65.4×**. Each dollar of revenue is priced at 65.4×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 8.1×**. The shares trade at 8.1× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -12.7%** (5-yr avg -7.2%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -852.6%**. Operating margin is negative: the business loses money before interest and tax.
- **Return on equity: -55.9%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -75.6%**. Return on all capital, debt included, is -75.6%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -40.4%**. Each dollar of assets produces -40.4% of profit.

## Growth
- **Revenue growth (1 yr): -35.3%** (3-yr -4.6%/yr, 5-yr -15.8%/yr). Revenue fell 35.3% over the last year, against -15.8% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -4.8%**. Earnings per share fell 4.8%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 0.16**. Debt is 0.16 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.3×**. It would take 0.3 years of operating earnings to repay net borrowings, within the comfortable range.
- **Piotroski F-score: 0/9**. 0 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Arcus Biosciences Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 156.6%** (YTD 24.5%, 3-mo 27.9%). The shares are up 156.6% over twelve months including dividends.
- **From 52-week high: -6.5%** (167.3% above the low). Trading 7% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 52**. An RSI of 52 is neutral.
- **Beta (1 yr): 1.78** (volatility 61%). Beta of 1.78 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=RCUS · Page: https://foliofundamentals.com/stocks/rcus

Not investment advice.